Abstract #1117
MRI at 7 T Correlates Therapy-Induced Alterations in T2 heterogeneity, ADC and Tumor Volume in Ewings Sarcoma Xenografts
Parastou Foroutan 1 , Christopher L Cubitt 2 , Jillaina L Menth 3 , Damon Reed 4 , Olya Grove 1 , David L Morse 1 , Daniel Sullivan 5 , Robert J Gillies 1 , and Gary V Martinez 1
1
Cancer Imaging & Metabolism, H. Lee Moffitt
Cancer Center & Research Institute, Tampa, FL, United
States,
2
Experimental
Therapeutics Program / Translational Research Lab, H.
Lee Moffitt Cancer Center & Research Institute, Tampa,
FL, United States,
3
Translational
Research Lab, H. Lee Moffitt Cancer Center & Research
Institute, Tampa, FL, United States,
4
Experimental
Therapeutics Program / Sarcoma Program, H. Lee Moffitt
Cancer Center & Research Institute, Tampa, FL, United
States,
5
Experimental
Therapeutics Program, H. Lee Moffitt Cancer Center &
Research Institute, Tampa, FL, United States
In spite of the progress with targeted therapies,
response rates for Ewings sarcoma (ES), one of the most
aggressive human malignancies, still remains poor. In
addition, imaging approaches assessing therapeutic
response is lacking, as current indices
(volume/diameter) do not accurately correlate with
changes in tumor biology. Herein, profound MRI analyses
were developed to evaluate imaging biomarkers for
Dasatinib and Triciribine treated ES xenografts.
Notably, we showed that inhibited tumor growth was
presaged by elevations in ADC, ADC distribution and T2
heterogeneity. This approach accentuates the role of ADC
as a quantitative imaging biomarker for response and
shows promising clinical relevance in the sarcoma
patient population.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
